“The expert group on the IDSA guidelines concluded that higher certainty benefits (eg reduction in mortality) for the use of these treatments are now highly unlikely even though additional high data. quality would become available, ”the group said in a statement obtained by Bloomberg News.
ISDA says it based its recommendations on trials of the drug. A study cited by ISDA found that COVID-19 patients treated with hydroxychloroquine who were not on ventilators “were more likely to be placed on mechanical ventilation during follow-up.”
Trump took the drug to avoid contracting COVID-19 earlier this year and has repeatedly praised the drug as a treatment for the virus.
Demand for hydroxychloroquine skyrocketed after Trump started promoting it, leading to shortages. The drug is not approved to treat COVID-19, but it is used to treat lupus, arthritis, and malaria. Doctors have warned, however, that the drug can cause serious heart problems.
U.S. health officials initially cleared the drugs for use as a potential treatment, but follow-up studies have led to cancellations from the Food and Drug Administration as well as the National Institutes of Health.